Belumosudil
Orphan DrugFDA Approved
Contents
Description
Belumosudil is a selective ROCK2 inhibitor approved for chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy. It works by modulating immune cell trafficking and inflammatory responses. The drug represents a novel mechanism for managing refractory chronic GVHD.
Indications & Therapeutic Use
chronic graft-versus-host disease
Linked Diseases:
graft-versus-host disease
T86.0D006086
Global Availability (2 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — |
Buy / Source Belumosudil — GNH India
4 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Belumosudil products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Belumosudil
| Generic Name | belumosudil |
| Brands | 1 brand available |
| Active Ingredient | belumosudil mesylate |
| Drug Class | chronic graft-versus-host disease |
| Manufacturer | Kadmon Pharmaceuticals |
| Dosage Forms | Oral tablet, 200mg |
| Medical Code | L04AX09 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT03640481 |
| Countries | 2 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations3 Validated Nodes